Yang Zhaoyun, Wang Yizhen, Yu Qin, Wang Shouli, Kong Derun
Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Digestive Endoscopy Center, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Evid Based Complement Alternat Med. 2022 Jun 15;2022:6837791. doi: 10.1155/2022/6837791. eCollection 2022.
To assess the efficacy of endoscopic intervention plus growth inhibitor and patient self-management in the treatment of esophagogastric variceal bleeding.
Between January 2019 and December 2021, 60 patients with esophagogastric variceal bleeding treated in our hospital were assessed for eligibility and randomly recruited. They were concurrently and randomly assigned at a ratio of 1 : 1 to receive either endoscopic intervention plus growth inhibitor (control group) or endoscopic intervention plus growth inhibitor and patient self-management (observation group). The endpoint is clinical efficacy.
All eligible patients showed a similar time of hemostasis, success rate of hemostasis, rebleeding rate, and disappearance rate of varicose veins ( > 0.05). Endoscopic intervention plus growth inhibitor and patient self-management were associated with a lower incidence of complication (6.67%, including 1 (3.34%) case of ulcer and 1 (3.34%) case of fever) than endoscopic intervention plus growth inhibitor (26.67%, including 3 (10.00%) cases of ulcer, 2 (6.67%) cases of retrosternal pain, and 3 (10.00%) cases of fever) ( < 0.05). Patients in the observation group had significantly higher life satisfaction scores (25.17 ± 4.28 and 23.68 ± 5.17) than those in the control group (22.13 ± 2.24 and 18.12 ± 3.28) ( < 0.05). A decrease in life satisfaction scores was observed at 6 months after treatment, and the patients given patient self-management showed a higher satisfaction ( < 0.05).
Endoscopic intervention plus growth inhibitor and patient self-management yielded remarkable clinical efficacy in the treatment of esophagogastric variceal bleeding as it reduces the incidence of complication and enhances the life satisfaction of patients, and so it is worthy of clinical promotion.
评估内镜干预联合生长抑素及患者自我管理在食管胃静脉曲张出血治疗中的疗效。
2019年1月至2021年12月，对我院收治的60例食管胃静脉曲张出血患者进行资格评估并随机招募。他们以1∶1的比例同时随机分为两组，分别接受内镜干预联合生长抑素治疗（对照组）或内镜干预联合生长抑素及患者自我管理治疗（观察组）。观察终点为临床疗效。
所有符合条件的患者止血时间、止血成功率、再出血率及静脉曲张消失率相似（P>0.05）。与内镜干预联合生长抑素治疗（26.67%，包括3例（10.00%）溃疡、2例（6.67%）胸骨后疼痛和3例（10.00%）发热）相比，内镜干预联合生长抑素及患者自我管理治疗的并发症发生率较低（6.67%，包括1例（3.34%）溃疡和1例（3.34%）发热）（P<0.05）。观察组患者的生活满意度评分（25.17±4.28和23.68±5.17）显著高于对照组（22.13±2.24和18.12±3.28）（P<0.05）。治疗后6个月观察到生活满意度评分下降，接受患者自我管理的患者满意度更高（P<0.05）。
内镜干预联合生长抑素及患者自我管理在食管胃静脉曲张出血治疗中具有显著的临床疗效，因为它降低了并发症的发生率，提高了患者的生活满意度，值得临床推广。
